{"url_path":"/sec/xlo/8-k/2026-05-12/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1840233/0001193125-26-218194-index.html","accession_number":"0001193125-26-218194","cik":"0001840233","ticker":"XLO","issuer_name":"Xilio Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1840233/0001193125-26-218194-index.html","primary_entity_key":"0001840233","primary_entity_name":"Xilio Therapeutics, Inc."},"word_count":112,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits.\n\n \n\nThe following exhibit relating to Item 2.02 of this Current Report on Form 8-K shall be deemed to be furnished and not filed.\n\n \n\n \n\n \n\nExhibit No.\n\nDescription\n\n99.1\n\n[Press release issued by Xilio Therapeutics, Inc. on May 12, 2026](xlo-ex99_1.htm)\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document and incorporated as Exhibit 101)\n\n \n\nSIGNATURES\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \n\n \n\nXILIO THERAPEUTICS, INC.\n\n \n\n \n\n \n\nDate: May 12, 2026\n\nBy:\n\n/s/ Caroline Hensley\n\n \n\n \n\nCaroline Hensley\n\n \n\n \n\nChief Legal Officer"}